Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
iTeos Therapeutics, Inc. Banner

iTeos Therapeutics, Inc.

ITOS Stock Analysis

Page title

Section title

About iTeos Therapeutics, Inc.

Biotechnology
Healthcare

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

iTeos Therapeutics, Inc. Key Metrics

Market Cap
$416M
52 Weeks Low
$8.20
52 Weeks High
$18.75
P/B
0.68x
P/E
-4.18x
P/S
17.54x

Upcoming Events

    ITOS Analyst Forecasts

    ‌
    ‌

    ITOS Financials

    ITOS Income Statement Key Metrics

    • Revenue(TTM)23.70 M
    • Gross Profit(TTM)22.63 M
    • EBITDA(TTM)-139.81 M
    • Net Income(TTM)-108.14 M
    • EPS Diluted(TTM)-3

    Decode ITOS's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    ITOS earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of ITOS (0.929) is higher than the average of its peers (0.305).

    Net Profit Margin vs Peers

    Net profit margin ratio of ITOS (-8.943) is lower than the average of its peers (-3.135).

    ITOS Return on Equity

    See how efficiently ITOS generates profit for it's shareholders.

    -19.58%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of ITOS (-0.196) is higher than the average of its peers (-0.784).

    Return on Equity Growth

    ITOS's Return on Equity has shown poor growth over the past 10 years, increasing by only -26.07%.

    ITOS Revenue Growth

    See how ITOS has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    ITOS's revenue has grown significantly over the past 10 years, increasing by over 0%.